NCT02860923View on ClinicalTrials.gov

Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions

CraniopharyngiomasHypothalamic Obesity

Interventions

DRUG

Exenatide

DRUG

Placebo

Trial Locations (11)

Unknown

CHU d'Angers, Angers

CHU de Brest, Brest

CHU de Grenoble, Grenoble

CHU de Lyon, Lyon

APHM, Marseille

Hôpital Bicêtre, Paris

Hôpital Cochin, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Pitié Salpétrière (APHP), Paris

Hôpital Haut-Lévêque, Pessac

CHU de Toulouse, Toulouse

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy | Biotech Hunter | Biotech Hunter